Understanding FcRn - Targeted Therapies: A Practical Guide for Home-Infusion Clinicians

 Neonatal Fc receptor (FcRn)–targeted therapies have expanded the treatment landscape for immunoglobulin G (IgG)–mediated autoimmune and inflammatory conditions, currently including FDA-approved indications such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). These therapies offer a non–plasma-derived strategy for reducing pathogenic IgG and have gained increasing relevance in the home infusion setting. As FcRn inhibitors transition from hospital-based and outpatient infusion centers to the specialty pharmacy and home infusion environment, many pharmacists and nurses are encountering FcRn inhibitors for the first time. While these agents share a common mechanism of action, their clinical implications, particularly related to infection risk, patient selection, and outcome assessment, require a clear, practical understanding within clinical practice workflows. This article provides a practical, approachable foundation for clinicians who are new to FcRn inhibitors. By the end of this review, pharmacists will understand the FcRN inhibitor mechanisms of action, be prepared to dispense these therapies safely, and effectively monitor patients across the continuum of care. Nurses will understand administration considerations, patient education needs and safety monitoring requirements throughout therapy.

Learning Objectives:

1. Explain the role of the neonatal Fc receptor (FcRn) in immunoglobulin G homeostasis and describe how FDA approved FcRn inhibitors work, including key differences in route of administration and labeled indications relevant to home infusion.
2. Conduct a complete pre-initiation assessment by verifying diagnosis and antibody status, reviewing baseline laboratory parameters and comorbidities, evaluating infection history, immunosuppressive therapy, vaccination status, and determining the appropriate site of care.
3. Implement structured, interdisciplinary monitoring throughout therapy, including infection surveillance, laboratory trend review, adherence assessment, and the application of baseline and ongoing outcome measures to evaluate clinical response.
4. Apply essential nursing and patient education strategies, covering administration technique, safety considerations, symptom reporting, and adherence support; to promote safe, effective use of FcRn targeted therapies in the home infusion setting.

NHIA General CE Information